Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test
Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.
You may also be interested in...
IV BioHoldings CEO Marty Keiser connects data, technology, capital and people to create start-ups focusing on liquid biopsy programs.
Foundation Medicine and Novartis’ commercial partnership has achieved another success as Foudation’s Liquid CDx is approved.
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.